Clinical Trials Browser

Withdrawn × belantamab mafodotin × Plasma cell × Clear all

NCT04398680 2025-12-04

DREAMM 13

Phase 1 Withdrawn

Multiple Myeloma, Recurrence

NCT05493618 2023-01-27

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Phase 1/2 Withdrawn

Multiple Myeloma